Antiviral Activity of Oral Probiotics

NCT05374070 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-13

No results posted yet for this study

Summary

The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.

Conditions

Interventions

DIETARY_SUPPLEMENT

Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)

Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.

DIETARY_SUPPLEMENT

Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included

In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.

DIETARY_SUPPLEMENT

Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)

In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.

DIETARY_SUPPLEMENT

Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included

In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.

Sponsors & Collaborators

  • John Hale

    lead INDUSTRY

Principal Investigators

  • John D Hale, PhD · Blis Technologies Ltd, Dunedin, New Zealand

  • John R Tagg, PhD · Blis Technologies Ltd, Dunedin, New Zealand

  • Liam Harold, PhD · Blis Technologies Ltd, Dunedin, New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2022-06-23
Completion
2022-08-15

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05374070 on ClinicalTrials.gov